메뉴 건너뛰기




Volumn 7, Issue 5, 2010, Pages 334-340

The good and evil of complement activation in HIV-1 infection

Author keywords

antibody; complement; HIV 1; human CD59

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CD59 ANTIGEN; CD59 MONOCLONAL ANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; EPITOPE; MANNOSE BINDING LECTIN; PEPTIDE; RECOMBINANT DOMAIN 4 OF INTERMEDILYSIN; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

EID: 77957660350     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.8     Document Type: Review
Times cited : (57)

References (149)
  • 1
    • 34447336141 scopus 로고    scopus 로고
    • The complement system in liver diseases
    • Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol 2006; 3: 333-340.
    • (2006) Cell Mol Immunol , vol.3 , pp. 333-340
    • Qin, X.1    Gao, B.2
  • 2
    • 52949138251 scopus 로고    scopus 로고
    • The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy
    • Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954-966.
    • (2008) Oncologist , vol.13 , pp. 954-966
    • Zhou, X.1    Hu, W.2    Qin, X.3
  • 3
    • 20944444434 scopus 로고    scopus 로고
    • "Homologous restriction" in complement lysis: Roles of membrane complement regulators
    • Morgan BP, Berg CW, Harris CL. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 2005; 12: 258-265.
    • (2005) Xenotransplantation , vol.12 , pp. 258-265
    • Morgan, B.P.1    Berg, C.W.2    Harris, C.L.3
  • 4
    • 0033064619 scopus 로고    scopus 로고
    • Regulation of the complement membrane attack pathway
    • Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol 1999; 19: 173-198. (Pubitemid 29321438)
    • (1999) Critical Reviews in Immunology , vol.19 , Issue.3 , pp. 173-198
    • Morgan, B.P.1
  • 5
    • 0035810399 scopus 로고    scopus 로고
    • Complement. First of two parts
    • Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
    • (2001) N Engl J Med , vol.344 , pp. 1058-1066
    • Walport, M.J.1
  • 6
    • 0021215772 scopus 로고
    • Complement. Historical perspectives and some current issues
    • Mayer MM. Complement. Historical perspectives and some current issues. Complement 1984; 1: 2-26.
    • (1984) Complement , vol.1 , pp. 2-26
    • Mayer, M.M.1
  • 8
    • 0022465626 scopus 로고
    • Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein
    • DOI 10.1084/jem.163.5.1150
    • Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 1986; 163: 1150-1161. (Pubitemid 16000414)
    • (1986) Journal of Experimental Medicine , vol.163 , Issue.5 , pp. 1150-1161
    • Davitz, M.A.1    Low, M.G.2    Nussenzweig, V.3
  • 9
    • 0021922659 scopus 로고
    • Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria
    • Nicholson-Weller A, Spicer DB, Austen KF. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 1985; 312: 1091-1097.
    • (1985) N Engl J Med , vol.312 , pp. 1091-1097
    • Nicholson-Weller, A.1    Spicer, D.B.2    Austen, K.F.3
  • 10
    • 0034292339 scopus 로고    scopus 로고
    • Cooperation between decay-accelerating factor membrane cofactor protein in protecting cells from autologous complement attack
    • Brodbeck WG, Mold C, Atkinson JP, Medof ME. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol 2000; 165: 3999-4006. (Pubitemid 32057311)
    • (2000) Journal of Immunology , vol.165 , Issue.7 , pp. 3999-4006
    • Brodbeck, W.G.1    Mold, C.2    Atkinson, J.P.3    Medof, M.E.4
  • 12
    • 0346656612 scopus 로고    scopus 로고
    • Complement and complement regulatory proteins as potential molecular targets for vascular diseases
    • DOI 10.2174/1381612043453441
    • Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 2004; 10: 203-211. (Pubitemid 38072756)
    • (2004) Current Pharmaceutical Design , vol.10 , Issue.2 , pp. 203-211
    • Acosta, J.1    Qin, X.2    Halperin, J.3
  • 13
    • 0038664378 scopus 로고    scopus 로고
    • Role of complement in the control of HIV dynamics and pathogenesis
    • DOI 10.1016/S0264-410X(03)00203-2
    • Stoiber H, Speth C, Dierich MP. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 2003; 21(Suppl 2): S77-S82. (Pubitemid 36588652)
    • (2003) Vaccine , vol.21 , Issue.SUPPL. 2
    • Stoiber, H.1    Speth, C.2    Dierich, M.P.3
  • 14
  • 15
    • 0025202520 scopus 로고
    • Activation of the complement system in human immunodeficiency virus infection: Relevance of the classical pathway to pathogenesis and disease severity
    • Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990; 162: 1227-1232.
    • (1990) J Infect Dis , vol.162 , pp. 1227-1232
    • Senaldi, G.1    Peakman, M.2    McManus, T.3    Davies, E.T.4    Tee, D.E.5    Vergani, D.6
  • 16
    • 0027393761 scopus 로고
    • Complement activation by human monoclonal antibodies to human immunodeficiency virus
    • Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993; 67: 53-59.
    • (1993) J Virol , vol.67 , pp. 53-59
    • Spear, G.T.1    Takefman, D.M.2    Sullivan, B.L.3    Landay, A.L.4    Zolla-Pazner, S.5
  • 17
    • 33845288582 scopus 로고    scopus 로고
    • Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    • Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006; 3: e441.
    • (2006) PLoS Med , vol.3
    • Huber, M.1    Fischer, M.2    Misselwitz, B.3    Manrique, A.4    Kuster, H.5    Niederost, B.6
  • 18
    • 0025719309 scopus 로고
    • Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41
    • Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174: 1417-1424.
    • (1991) J Exp Med , vol.174 , pp. 1417-1424
    • Ebenbichler, C.F.1    Thielens, N.M.2    Vornhagen, R.3    Marschang, P.4    Arlaud, G.J.5    Dierich, M.P.6
  • 19
    • 0025880239 scopus 로고
    • Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells
    • Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991; 7: 579-585.
    • (1991) AIDS Res Hum Retroviruses , vol.7 , pp. 579-585
    • Spear, G.T.1    Jiang, H.X.2    Sullivan, B.L.3    Gewurz, H.4    Landay, A.L.5    Lint, T.F.6
  • 20
    • 0027372368 scopus 로고
    • Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins
    • Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993; 7: 1307-1313.
    • (1993) AIDS , vol.7 , pp. 1307-1313
    • Haurum, J.S.1    Thiel, S.2    Jones, I.M.3    Fischer, P.B.4    Laursen, S.B.5    Jensenius, J.C.6
  • 21
    • 0027454001 scopus 로고
    • Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1
    • Thielens NM, Bally IM, Ebenbichler CF, Dierich MP, Arlaud GJ. Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 1993; 151: 6583-6592. (Pubitemid 23340405)
    • (1993) Journal of Immunology , vol.151 , Issue.11 , pp. 6583-6592
    • Thielens, N.M.1    Bally, I.M.2    Ebenbichler, C.F.3    Dierich, M.P.4    Arlaud, G.J.5
  • 23
    • 0027979727 scopus 로고
    • The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology
    • Stoiber H, Thielens NM, Ebenbichler C, Arlaud GJ, Dierich MP. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 1994; 24: 294-300.
    • (1994) Eur J Immunol , vol.24 , pp. 294-300
    • Stoiber, H.1    Thielens, N.M.2    Ebenbichler, C.3    Arlaud, G.J.4    Dierich, M.P.5
  • 24
    • 0028833387 scopus 로고
    • Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1
    • Stoiber H, Ebenbichler C, Schneider R, Janatova J, Dierich MP. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 1995; 9: 19-26.
    • (1995) AIDS , vol.9 , pp. 19-26
    • Stoiber, H.1    Ebenbichler, C.2    Schneider, R.3    Janatova, J.4    Dierich, M.P.5
  • 25
    • 0029869284 scopus 로고    scopus 로고
    • Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120
    • Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120. Blood 1996; 87: 2329-2336. (Pubitemid 26086874)
    • (1996) Blood , vol.87 , Issue.6 , pp. 2329-2336
    • Susal, C.1    Kirschfink, M.2    Kropelin, M.3    Daniel, V.4    Opelz, G.5
  • 28
    • 0032168058 scopus 로고    scopus 로고
    • Complement can neutralizeHIV-1 plasma virus by a C5-independent mechanism
    • Sullivan BL, Takefman DM, Spear GT. Complement can neutralizeHIV-1 plasma virus by a C5-independent mechanism. Virology 1998; 248: 173-181.
    • (1998) Virology , vol.248 , pp. 173-181
    • Sullivan, B.L.1    Takefman, D.M.2    Spear, G.T.3
  • 29
    • 0026970210 scopus 로고
    • Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis
    • Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses 1992; 8: 553-558. (Pubitemid 23130907)
    • (1992) AIDS Research and Human Retroviruses , vol.8 , Issue.5 , pp. 553-558
    • Posner, M.R.1    Elboim, H.S.2    Cannon, T.3    Cavacini, L.4    Hideshima, T.5
  • 30
    • 0031449456 scopus 로고    scopus 로고
    • Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV-1
    • DOI 10.1038/nm1297-1389
    • Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389-1393. (Pubitemid 28011040)
    • (1997) Nature Medicine , vol.3 , Issue.12 , pp. 1389-1393
    • Gauduin, M.-C.1    Parren, P.W.H.I.2    Weir, R.3    Barbas, C.F.4    Burton, D.R.5    Koup, R.A.6
  • 31
    • 0029162867 scopus 로고
    • Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CE59 in complement resistance of cell derived and primary isolates of HIV-1
    • Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CE59 in complement resistance of cell derived and primary isolates of HIV-1. J Exp Med 1995; 182: 501-509.
    • (1995) J Exp Med , vol.182 , pp. 501-509
    • Saifuddin, M.1    Parker, C.J.2    Peeples, M.E.3    Gorny, M.K.4    Zolla-Pazner, S.5    Ghassemi, M.6
  • 32
    • 0029090040 scopus 로고
    • Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59
    • Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 1995; 96: 1520-1526.
    • (1995) J Clin Invest , vol.96 , pp. 1520-1526
    • Schmitz, J.1    Zimmer, J.P.2    Kluxen, B.3    Aries, S.4    Bogel, M.5    Gigli, I.6
  • 33
  • 34
    • 34347214119 scopus 로고    scopus 로고
    • Humoral immunity to HIV-1: Neutralization and beyond
    • DOI 10.1111/j.1365-2796.2007.01819.x
    • Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262: 5-25. (Pubitemid 47000630)
    • (2007) Journal of Internal Medicine , vol.262 , Issue.1 , pp. 5-25
    • Huber, M.1    Trkola, A.2
  • 35
    • 34347256384 scopus 로고    scopus 로고
    • Inhibition of HIV-1 entry by antibodies: Potential viral and cellular targets
    • DOI 10.1111/j.1365-2796.2007.01820.x
    • Phogat S, Wyatt RT, Karlsson Hedestam GB. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007; 262: 26-43. (Pubitemid 47000631)
    • (2007) Journal of Internal Medicine , vol.262 , Issue.1 , pp. 26-43
    • Phogat, S.1    Wyatt, R.T.2    Karlsson, H.G.B.3
  • 36
    • 34250323791 scopus 로고    scopus 로고
    • HIV-1 rational vaccine design: Molecular details of b12-gp120 complex structure
    • DOI 10.1586/14760584.6.3.319
    • Phogat SK, Kaminsky SM, Koff WC. HIV-1 rational vaccine design: molecular details of b12-gp120 complex structure. Expert Rev Vaccines 2007; 6: 319-321. (Pubitemid 46911595)
    • (2007) Expert Review of Vaccines , vol.6 , Issue.3 , pp. 319-321
    • Phogat, S.K.1    Kaminsky, S.M.2    Koff, W.C.3
  • 37
    • 56649083541 scopus 로고    scopus 로고
    • Humoral immunity to HIV-1: Neutralisation and antibody effector functions
    • Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008; 16: 596-604.
    • (2008) Trends Microbiol , vol.16 , pp. 596-604
    • Willey, S.1    Aasa-Chapman, M.M.2
  • 38
    • 42049085289 scopus 로고    scopus 로고
    • Correlates of antibody-mediated protection against HIV infection
    • DOI 10.1097/COH.0b013e3282f9ae79, PII 0122292920080500000027
    • Sattentau Q. Correlates of antibody-mediated protection against HIV infection. Curr Opin HIV AIDS 2008; 3: 368-374. (Pubitemid 351521023)
    • (2008) Current Opinion in HIV and AIDS , vol.3 , Issue.3 , pp. 368-374
    • Sattentau, Q.1
  • 39
    • 0032546844 scopus 로고    scopus 로고
    • The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
    • DOI 10.1126/science.280.5371.1884
    • Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884-1888. (Pubitemid 28299385)
    • (1998) Science , vol.280 , Issue.5371 , pp. 1884-1888
    • Wyatt, R.1    Sodroski, J.2
  • 40
    • 0035222608 scopus 로고    scopus 로고
    • The antiviral activity of antibodies in vitro and in vivo
    • DOI 10.1016/S0065-2776(01)77018-6
    • Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001; 77: 195-262. (Pubitemid 33703707)
    • (2001) Advances in Immunology , vol.77 , pp. 195-262
    • Parren, P.W.H.I.1    Burton, D.R.2
  • 41
    • 0036436313 scopus 로고    scopus 로고
    • Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies
    • DOI 10.1089/08892220260387959
    • Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 2002; 18: 1207-1217. (Pubitemid 35370609)
    • (2002) AIDS Research and Human Retroviruses , vol.18 , Issue.16 , pp. 1207-1217
    • Xiang, S.-H.1    Doka, N.2    Choudhary, R.K.3    Sodroski, J.4    Robinson, J.E.5
  • 45
    • 33646146379 scopus 로고    scopus 로고
    • GP120: Target for neutralizing HIV-1 antibodies
    • Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24: 739-769.
    • (2006) Annu Rev Immunol , vol.24 , pp. 739-769
    • Pantophlet, R.1    Burton, D.R.2
  • 46
    • 0035991710 scopus 로고    scopus 로고
    • Neutralizing antibody responses to HIV-1 infection
    • DOI 10.1080/15216540212656
    • Morris L. Neutralizing antibody responses to HIV-1 infection. IUBMB Life 2002; 53: 197-199. (Pubitemid 34728926)
    • (2002) IUBMB Life , vol.53 , Issue.4-5 , pp. 197-199
    • Morris, L.1
  • 47
    • 0028321596 scopus 로고
    • Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers
    • Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 1994; 93: 2505-2513.
    • (1994) J Clin Invest , vol.93 , pp. 2505-2513
    • Pincus, S.H.1    Messer, K.G.2    Nara, P.L.3    Blattner, W.A.4    Colclough, G.5    Reitz, M.6
  • 48
    • 0029113691 scopus 로고
    • Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection
    • Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O et al. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 1995; 172: 691-697.
    • (1995) J Infect Dis , vol.172 , pp. 691-697
    • Belec, L.1    Dupre, T.2    Prazuck, T.3    Tevi-Benissan, C.4    Kanga, J.M.5    Pathey, O.6
  • 49
    • 0030897105 scopus 로고    scopus 로고
    • Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    • Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997; 71: 2799-2809. (Pubitemid 27119919)
    • (1997) Journal of Virology , vol.71 , Issue.4 , pp. 2799-2809
    • Binley, J.M.1    Klasse, P.J.2    Cao, Y.3    Jones, I.4    Markowitz, M.5    Ho, D.D.6    Moore, J.P.7
  • 53
    • 33745890578 scopus 로고    scopus 로고
    • The role of neutralizing antibodies in HIV infection
    • Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006; 8: 51-59. (Pubitemid 44043554)
    • (2006) AIDS Reviews , vol.8 , Issue.2 , pp. 51-59
    • Humbert, M.1    Dietrich, U.2
  • 58
    • 0035701421 scopus 로고    scopus 로고
    • A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
    • DOI 10.1089/08892220152741450
    • Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17: 1757-1765. (Pubitemid 34114213)
    • (2001) AIDS Research and Human Retroviruses , vol.17 , Issue.18 , pp. 1757-1765
    • Stiegler, G.1    Kunert, R.2    Purtscher, M.3    Wolbank, S.4    Voglauer, R.5    Steindl, F.6    Katinger, H.7
  • 59
    • 0028235930 scopus 로고
    • Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
    • Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994; 68: 4031-4034. (Pubitemid 24177431)
    • (1994) Journal of Virology , vol.68 , Issue.6 , pp. 4031-4034
    • Muster, T.1    Guinea, R.2    Trkola, A.3    Purtscher, M.4    Klima, A.5    Steindl, F.6    Palese, P.7    Katinger, H.8
  • 60
    • 0028593629 scopus 로고
    • A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1
    • Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994; 10: 1651-1658.
    • (1994) AIDS Res Hum Retroviruses , vol.10 , pp. 1651-1658
    • Purtscher, M.1    Trkola, A.2    Gruber, G.3    Buchacher, A.4    Predl, R.5    Steindl, F.6
  • 62
    • 0028291731 scopus 로고
    • Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
    • Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68: 4821-4828. (Pubitemid 24226546)
    • (1994) Journal of Virology , vol.68 , Issue.8 , pp. 4821-4828
    • Roben, P.1    Moore, J.P.2    Thali, M.3    Sodroski, J.4    Barbas III, C.F.5    Burton, D.R.6
  • 63
    • 27944455654 scopus 로고    scopus 로고
    • HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: In vitro experiments versus clinical studies
    • Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 2005; 19: 1957-1966. (Pubitemid 41669019)
    • (2005) AIDS , vol.19 , Issue.17 , pp. 1957-1966
    • Nakowitsch, S.1    Quendler, H.2    Fekete, H.3    Kunert, R.4    Katinger, H.5    Stiegler, G.6
  • 64
    • 34547808791 scopus 로고    scopus 로고
    • In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    • Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007; 81: 8793-8808.
    • (2007) J Virol , vol.81 , pp. 8793-8808
    • Manrique, A.1    Rusert, P.2    Joos, B.3    Fischer, M.4    Kuster, H.5    Leemann, C.6
  • 65
    • 18244422922 scopus 로고    scopus 로고
    • The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120
    • Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002; 76: 7306-7321.
    • (2002) J Virol , vol.76 , pp. 7306-7321
    • Scanlan, C.N.1    Pantophlet, R.2    Wormald, M.R.3    Ollmann Saphire, E.4    Stanfield, R.5    Wilson, I.A.6
  • 68
    • 13844255333 scopus 로고    scopus 로고
    • Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    • DOI 10.1016/j.immuni.2004.12.011
    • Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22: 163-173. (Pubitemid 40255708)
    • (2005) Immunity , vol.22 , Issue.2 , pp. 163-173
    • Cardoso, R.M.F.1    Zwick, M.B.2    Stanfield, R.L.3    Kunert, R.4    Binley, J.M.5    Katinger, H.6    Burton, D.R.7    Wilson, I.A.8
  • 72
    • 20944446452 scopus 로고    scopus 로고
    • Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    • Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 615-622.
    • (2005) Nat Med , vol.11 , pp. 615-622
    • Trkola, A.1    Kuster, H.2    Rusert, P.3    Joos, B.4    Fischer, M.5    Leemann, C.6
  • 73
    • 0000604395 scopus 로고    scopus 로고
    • The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
    • Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999; 13(Suppl A): S137-S162.
    • (1999) AIDS , vol.13 , Issue.SUPPL. A
    • Parren, P.W.1    Moore, J.P.2    Burton, D.R.3    Sattentau, Q.J.4
  • 77
    • 33745203490 scopus 로고    scopus 로고
    • Distribution and three-dimensional structure of AIDS virus envelope spikes
    • Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441: 847-852.
    • (2006) Nature , vol.441 , pp. 847-852
    • Zhu, P.1    Liu, J.2    Bess Jr., J.3    Chertova, E.4    Lifson, J.D.5    Grise, H.6
  • 78
    • 0025572710 scopus 로고
    • Dissociation of gp120 from HIV-1 virions induced by soluble CD4
    • Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990; 250: 1139-1142. (Pubitemid 120031823)
    • (1990) Science , vol.250 , Issue.4984 , pp. 1139-1142
    • Moore, J.P.1    Mckeating, J.A.2    Weiss, R.A.3    Sattentau, Q.J.4
  • 79
    • 0026098303 scopus 로고
    • Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization
    • McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol 1991; 65: 852-860.
    • (1991) J Virol , vol.65 , pp. 852-860
    • McKeating, J.A.1    McKnight, A.2    Moore, J.P.3
  • 80
    • 0037213278 scopus 로고    scopus 로고
    • Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies
    • DOI 10.1128/JVI.77.1.353-365.2003
    • Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003; 77: 353-365. (Pubitemid 36004975)
    • (2003) Journal of Virology , vol.77 , Issue.1 , pp. 353-365
    • Poignard, P.1    Moulard, M.2    Golez, E.3    Vivona, V.4    Franti, M.5    Venturini, S.6    Wang, M.7    Parren, P.W.H.I.8    Burton, D.R.9
  • 81
    • 1842613542 scopus 로고    scopus 로고
    • HIV-1 dynamics in vivo: Implications for therapy
    • Simon V, Ho DD. HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 2003; 1: 181-190.
    • (2003) Nat Rev Microbiol , vol.1 , pp. 181-190
    • Simon, V.1    Ho, D.D.2
  • 83
    • 33750297873 scopus 로고    scopus 로고
    • HIV evolutionary dynamics within and among hosts
    • Lemey P, Rambaut A, Pybus OG. HIV evolutionary dynamics within and among hosts. AIDS Rev 2006; 8: 125-140. (Pubitemid 44614030)
    • (2006) AIDS Reviews , vol.8 , Issue.3 , pp. 125-140
    • Lemey, P.1    Rambaut, A.2    Pybus, O.G.3
  • 85
    • 63849116536 scopus 로고    scopus 로고
    • Mechanisms of protection against rotavirus infection and disease
    • Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 2009; 28: S57-59.
    • (2009) Pediatr Infect Dis J , vol.28
    • Ward, R.1
  • 86
    • 0021246636 scopus 로고
    • Monoclonal antibodies protect against respiratory syncytial virus infection in mice
    • Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 1984; 52: 137-142. (Pubitemid 14136692)
    • (1984) Immunology , vol.52 , Issue.1 , pp. 137-142
    • Taylor, G.1    Stott, E.J.2    Bew, M.3
  • 88
    • 33646163652 scopus 로고    scopus 로고
    • A review of vaccine research and development: The human immunodeficiency virus (HIV)
    • Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006; 24: 4062-4081.
    • (2006) Vaccine , vol.24 , pp. 4062-4081
    • Girard, M.P.1    Osmanov, S.K.2    Kieny, M.P.3
  • 89
    • 52449104809 scopus 로고    scopus 로고
    • DNA vaccines: Ready for prime time?
    • Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9: 776-788.
    • (2008) Nat Rev Genet , vol.9 , pp. 776-788
    • Kutzler, M.A.1    Weiner, D.B.2
  • 90
    • 56149095844 scopus 로고    scopus 로고
    • Immunogenicity of DNA vaccines in humans: It takes two to tango
    • Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008; 4: 449-452.
    • (2008) Hum Vaccin , vol.4 , pp. 449-452
    • Lu, S.1
  • 91
    • 36148973173 scopus 로고    scopus 로고
    • HIV/AIDS vaccines: 2007
    • Robinson HL. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007; 82: 686-693.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 686-693
    • Robinson, H.L.1
  • 92
    • 42049083555 scopus 로고    scopus 로고
    • T cell responses generated by HIV vaccines in clinical trials
    • DOI 10.1097/COH.0b013e3282fbaaa7, PII 0122292920080500000028
    • De Rosa SD, McElrath MJ. T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 2008; 3: 375-379. (Pubitemid 351521024)
    • (2008) Current Opinion in HIV and AIDS , vol.3 , Issue.3 , pp. 375-379
    • De, R.S.D.1    McElrath, M.J.2
  • 93
    • 0037404791 scopus 로고    scopus 로고
    • Live recombinant vectors for AIDS vaccine development
    • DOI 10.2174/1566524033479816
    • Voltan R, Robert-Guroff M. Live recombinant vectors for AIDS vaccine development. Curr Mol Med 2003; 3: 273-284. (Pubitemid 36443225)
    • (2003) Current Molecular Medicine , vol.3 , Issue.3 , pp. 273-284
    • Voltan, R.1    Robert-Guroff, M.2
  • 94
    • 0036787478 scopus 로고    scopus 로고
    • A new generation of HIV vaccines
    • Amara RR, Robinson HL. A new generation of HIV vaccines. Trends Mol Med 2002; 8: 489-495.
    • (2002) Trends Mol Med , vol.8 , pp. 489-495
    • Amara, R.R.1    Robinson, H.L.2
  • 95
    • 48149108390 scopus 로고    scopus 로고
    • Designing an effective AIDS vaccine: Strategies and current status
    • French
    • Coutsinos Z, Absi Z, Henin Y, Guillet JG, Launay O. Designing an effective AIDS vaccine: strategies and current status. Rev Med Interne 2008; 29: 632-641. French
    • (2008) Rev Med Interne , vol.29 , pp. 632-641
    • Coutsinos, Z.1    Absi, Z.2    Henin, Y.3    Guillet, J.G.4    Launay, O.5
  • 96
    • 33746192136 scopus 로고    scopus 로고
    • HIV/AIDS preventive vaccine 'prime-boost' phase III trial: Foundations and initial lessons learned from Thailand
    • Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006; 20: 1471-1479.
    • (2006) AIDS , vol.20 , pp. 1471-1479
    • Rerks-Ngarm, S.1    Brown, A.E.2    Khamboonruang, C.3    Thongcharoen, P.4    Kunasol, P.5
  • 97
    • 14544290129 scopus 로고    scopus 로고
    • Progress toward an HIV vaccine
    • DOI 10.1146/annurev.med.54.101601.152349
    • Letvin NL. Progress toward an HIV vaccine. Annu Rev Med 2005; 56: 213-223. (Pubitemid 40299781)
    • (2005) Annual Review of Medicine , vol.56 , pp. 213-223
    • Letvin, N.L.1
  • 98
    • 44049108744 scopus 로고    scopus 로고
    • Toward an AIDS vaccine
    • DOI 10.1126/science.1152622
    • Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320: 760-764. (Pubitemid 351929619)
    • (2008) Science , vol.320 , Issue.5877 , pp. 760-764
    • Walker, B.D.1    Burton, D.R.2
  • 100
    • 69149083668 scopus 로고    scopus 로고
    • Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine?
    • Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15: 866-870.
    • (2009) Nat Med , vol.15 , pp. 866-870
    • Stamatatos, L.1    Morris, L.2    Burton, D.R.3    Mascola, J.R.4
  • 101
    • 70349887757 scopus 로고    scopus 로고
    • Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    • Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-289.
    • (2009) Science , vol.326 , pp. 285-289
    • Walker, L.M.1    Phogat, S.K.2    Chan-Hui, P.Y.3    Wagner, D.4    Phung, P.5    Goss, J.L.6
  • 102
    • 5444248711 scopus 로고    scopus 로고
    • Mannose binding lectin (MBL) and HIV
    • Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol 2005; 42: 145-152.
    • (2005) Mol Immunol , vol.42 , pp. 145-152
    • Ji, X.1    Gewurz, H.2    Spear, G.T.3
  • 103
    • 0024584844 scopus 로고
    • A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus
    • DOI 10.1084/jem.169.1.185
    • Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 1989; 169: 185-196. (Pubitemid 19035551)
    • (1989) Journal of Experimental Medicine , vol.169 , Issue.1 , pp. 185-196
    • Ezekowitz, R.A.B.1    Kuhlman, M.2    Groopman, J.E.3    Byrn, R.A.4
  • 104
    • 0034028110 scopus 로고    scopus 로고
    • Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1
    • Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000; 81: 949-955. (Pubitemid 30189633)
    • (2000) Journal of General Virology , vol.81 , Issue.4 , pp. 949-955
    • Saifuddin, M.1    Hart, M.L.2    Gewurz, H.3    Zhang, Y.4    Spear, G.T.5
  • 105
    • 1842450254 scopus 로고    scopus 로고
    • Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization
    • DOI 10.1089/088922204322996563
    • Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 2004; 20: 327-335. (Pubitemid 38429405)
    • (2004) AIDS Research and Human Retroviruses , vol.20 , Issue.3 , pp. 327-335
    • Ying, H.1    Ji, X.2    Hart, M.L.3    Gupta, K.4    Saifuddin, M.5    Zariffard, M.R.6    Spear, G.T.7
  • 106
    • 0037311412 scopus 로고    scopus 로고
    • Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin
    • DOI 10.1099/vir.0.18734-0
    • Hart ML, Saifuddin M, Spear GT. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J Gen Virol 2003; 84: 353-360. (Pubitemid 36175709)
    • (2003) Journal of General Virology , vol.84 , Issue.2 , pp. 353-360
    • Hart, M.L.1    Saifuddin, M.2    Spear, G.T.3
  • 107
    • 46049088698 scopus 로고    scopus 로고
    • An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children
    • Singh KK, Lieser A, Ruan PK, Fenton T, Spector SA. An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol 2008; 122: 173-180, 180.e1-2.
    • (2008) J Allergy Clin Immunol , vol.122
    • Singh, K.K.1    Lieser, A.2    Ruan, P.K.3    Fenton, T.4    Spector, S.A.5
  • 108
    • 70450225061 scopus 로고    scopus 로고
    • Association between mannose-binding lectin and HIV infection and progression in a Chinese population
    • Tan Y, Liu L, Luo P, Wang A, Jia T, Shen X et al. Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol 2009; 47: 632-638.
    • (2009) Mol Immunol , vol.47 , pp. 632-638
    • Tan, Y.1    Liu, L.2    Luo, P.3    Wang, A.4    Jia, T.5    Shen, X.6
  • 110
    • 6344261596 scopus 로고    scopus 로고
    • Cutting edge: Productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18)
    • Bajtay Z, Speth C, Erdei A, Dierich MP. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 2004; 173: 4775-4778. (Pubitemid 39387756)
    • (2004) Journal of Immunology , vol.173 , Issue.8 , pp. 4775-4778
    • Bajtay, Z.1    Speth, C.2    Erdei, A.3    Dierich, M.P.4
  • 113
    • 0025076044 scopus 로고
    • Human leukocyte C1q receptor binds other soluble proteins with collagen domains
    • DOI 10.1084/jem.172.3.955
    • Malhotra R, Thiel S, Reid KB, Sim RB. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990; 172: 955-959. (Pubitemid 20301242)
    • (1990) Journal of Experimental Medicine , vol.172 , Issue.3 , pp. 955-959
    • Malhotra, R.1    Thiel, S.2    Reid, K.B.M.3    Sim, R.B.4
  • 114
    • 0027200478 scopus 로고
    • Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV
    • Delibrias CC, Kazatchkine MD, Fischer E. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 1993; 38: 183-189. (Pubitemid 23233545)
    • (1993) Scandinavian Journal of Immunology , vol.38 , Issue.2 , pp. 183-189
    • Delibrias, C.-C.1    Kazatchkine, M.D.2    Fischer, E.3
  • 115
    • 0028916065 scopus 로고
    • Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection
    • Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, Hansen JE. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 1995; 69: 2393-2400.
    • (1995) J Virol , vol.69 , pp. 2393-2400
    • Lund, O.1    Hansen, J.2    Soorensen, A.M.3    Mosekilde, E.4    Nielsen, J.O.5    Hansen, J.E.6
  • 116
    • 0031414824 scopus 로고    scopus 로고
    • Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): An accessory role for CR3 during virus entry?
    • DOI 10.1016/S0161-5890(97)00108-9, PII S0161589097001089
    • Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM et al. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol 1997; 34: 855-863. (Pubitemid 28086167)
    • (1997) Molecular Immunology , vol.34 , Issue.12-13 , pp. 855-863
    • Stoiber, H.1    Frank, I.2    Spruth, M.3    Schwendinger, M.4    Mullauer, B.5    Windisch, J.M.6    Schneider, R.7    Katinger, H.8    Ando, I.9    Dierich, M.P.10
  • 123
    • 0034605036 scopus 로고    scopus 로고
    • B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
    • Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000; 192: 637-646.
    • (2000) J Exp Med , vol.192 , pp. 637-646
    • Moir, S.1    Malaspina, A.2    Li, Y.3    Chun, T.W.4    Lowe, T.5    Adelsberger, J.6
  • 125
    • 0032904992 scopus 로고    scopus 로고
    • B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1
    • Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 1999; 96: 612-619.
    • (1999) Immunology , vol.96 , pp. 612-619
    • Jakubik, J.J.1    Saifuddin, M.2    Takefman, D.M.3    Spear, G.T.4
  • 126
    • 0033989551 scopus 로고    scopus 로고
    • Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes
    • Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol 2000; 74: 552-555. (Pubitemid 30002940)
    • (2000) Journal of Virology , vol.74 , Issue.1 , pp. 552-555
    • Jakubik, J.J.1    Saifuddin, M.2    Takefman, D.M.3    Spear, G.T.4
  • 127
    • 70149114859 scopus 로고    scopus 로고
    • A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement
    • Xu Y, Zhang C, Jia L, Wen C, Liu H, Wang Y et al. A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement. Virol J 2009; 6: 123.
    • (2009) Virol J , vol.6 , pp. 123
    • Xu, Y.1    Zhang, C.2    Jia, L.3    Wen, C.4    Liu, H.5    Wang, Y.6
  • 128
  • 129
    • 0030064149 scopus 로고    scopus 로고
    • Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)
    • DOI 10.1084/jem.183.1.307
    • Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996; 183: 307-310. (Pubitemid 26028772)
    • (1996) Journal of Experimental Medicine , vol.183 , Issue.1 , pp. 307-310
    • Stoiber, H.1    Pinter, C.2    Siccardi, A.G.3    Clivio, A.4    Dierich, M.P.5
  • 131
    • 0034015604 scopus 로고    scopus 로고
    • Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts
    • DOI 10.1128/JVI.74.7.3264-3272.2000
    • Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000; 74: 3264-3272. (Pubitemid 30143751)
    • (2000) Journal of Virology , vol.74 , Issue.7 , pp. 3264-3272
    • Nguyen, D.H.1    Hildreth, J.E.K.2
  • 132
    • 0036301911 scopus 로고    scopus 로고
    • Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack
    • DOI 10.1046/j.1365-2567.2002.01421.x
    • Rautemaa R, Helander T, Meri S. Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack. Immunology 2002; 106: 404-411. (Pubitemid 34748135)
    • (2002) Immunology , vol.106 , Issue.3 , pp. 404-411
    • Rautemaa, R.1    Helander, T.2    Meri, S.3
  • 134
    • 5444231475 scopus 로고    scopus 로고
    • Complement-opsonized HIV: The free rider on its way to infection
    • Stoiber H, Pruenster M, Ammann CG, Dierich MP. Complement-opsonized HIV: the free rider on its way to infection. Mol Immunol 2005; 42: 153-160.
    • (2005) Mol Immunol , vol.42 , pp. 153-160
    • Stoiber, H.1    Pruenster, M.2    Ammann, C.G.3    Dierich, M.P.4
  • 135
    • 31844440174 scopus 로고    scopus 로고
    • Identification of a Naegleria fowleri membrane protein reactive with anti-human CD59 antibody
    • DOI 10.1128/IAI.74.2.1189-1195.2006
    • Fritzinger AE, Toney DM, MacLean RC, Marciano-Cabral F. Identification of a Naegleria fowleri membrane protein reactive with anti-human CD59 antibody. Infect Immun 2006; 74: 1189-1195. (Pubitemid 43185558)
    • (2006) Infection and Immunity , vol.74 , Issue.2 , pp. 1189-1195
    • Fritzinger, A.E.1    Toney, D.M.2    MacLean, R.C.3    Marciano-Cabral, F.4
  • 136
    • 0030813504 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction
    • Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78: 1907-1911. (Pubitemid 27367673)
    • (1997) Journal of General Virology , vol.78 , Issue.8 , pp. 1907-1911
    • Saifuddin, M.1    Hedayati, T.2    Atkinson, J.P.3    Holguin, M.H.4    Parker, C.J.5    Spear, G.T.6
  • 137
    • 73949108246 scopus 로고    scopus 로고
    • A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: Implications for treatment of HIV-1/AIDS
    • Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 2010; 184: 359-368.
    • (2010) J Immunol , vol.184 , pp. 359-368
    • Hu, W.1    Yu, Q.2    Hu, N.3    Byrd, D.4    Amet, T.5    Shikuma, C.6
  • 138
    • 0035760902 scopus 로고    scopus 로고
    • CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
    • Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
    • (2001) Blood , vol.98 , pp. 3383-3389
    • Golay, J.1    Lazzari, M.2    Facchinetti, V.3    Bernasconi, S.4    Borleri, G.5    Barbui, T.6
  • 139
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908. (Pubitemid 30412866)
    • (2000) Blood , vol.95 , Issue.12 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3    Lazzari, M.4    Borleri, G.-M.5    Bernasconi, S.6    Tedesco, F.7    Rambaldi, A.8    Introna, M.9
  • 140
    • 33644866786 scopus 로고    scopus 로고
    • Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    • Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625-631.
    • (2006) Leuk Res , vol.30 , pp. 625-631
    • Takei, K.1    Yamazaki, T.2    Sawada, U.3    Ishizuka, H.4    Aizawa, S.5
  • 141
    • 22544462219 scopus 로고    scopus 로고
    • Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
    • DOI 10.1002/eji.200425920
    • Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175-2183. (Pubitemid 41015056)
    • (2005) European Journal of Immunology , vol.35 , Issue.7 , pp. 2175-2183
    • Ziller, F.1    Macor, P.2    Bulla, R.3    Sblattero, D.4    Marzari, R.5    Tedesco, F.6
  • 142
    • 79951970278 scopus 로고    scopus 로고
    • Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab
    • Macor P, Piovan E, Zorzet S, Tripodo C, Marzari R, Amadori A et al.Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab. Mol Immunol 2007; 44: 212.
    • (2007) Mol Immunol , vol.44 , pp. 212
    • Macor, P.1    Piovan, E.2    Zorzet, S.3    Tripodo, C.4    Marzari, R.5    Amadori, A.6
  • 143
    • 35948989248 scopus 로고    scopus 로고
    • In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
    • Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556-10563.
    • (2007) Cancer Res , vol.67 , pp. 10556-10563
    • Macor, P.1    Tripodo, C.2    Zorzet, S.3    Piovan, E.4    Bossi, F.5    Marzari, R.6
  • 144
    • 0032562686 scopus 로고    scopus 로고
    • Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59
    • DOI 10.1074/jbc.273.17.10665
    • Zhao XJ, Zhao J, Zhou Q, Sims PJ. Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59. J Biol Chem 1998; 273: 10665-10671. (Pubitemid 28227680)
    • (1998) Journal of Biological Chemistry , vol.273 , Issue.17 , pp. 10665-10671
    • Zhao, X.-J.1    Zhao, J.2    Zhou, Q.3    Sims, P.J.4
  • 145
    • 0031041068 scopus 로고    scopus 로고
    • Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59
    • DOI 10.1084/jem.185.3.507
    • Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997; 185: 507-516. (Pubitemid 27078369)
    • (1997) Journal of Experimental Medicine , vol.185 , Issue.3 , pp. 507-516
    • Bodian, D.L.1    Davis, S.J.2    Morgan, B.P.3    Rushmere, N.K.4
  • 146
    • 0029880993 scopus 로고    scopus 로고
    • Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59
    • DOI 10.1021/bi952862w
    • Husler T, Lockert DH, Sims PJ. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59. Biochemistry 1995; 35: 3263-3269. (Pubitemid 26082254)
    • (1996) Biochemistry , vol.35 , Issue.10 , pp. 3263-3269
    • Husler, T.1    Lockert, D.H.2    Sims, P.J.3
  • 147
    • 34249054072 scopus 로고    scopus 로고
    • Crystal structure of CD59: Implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex
    • DOI 10.1107/S0907444907015557, PII S0907444907015557
    • Huang Y, Fedarovich A, Tomlinson S, Davies C. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallogr D Biol Crystallogr 2007; 63: 714-721. (Pubitemid 46787696)
    • (2007) Acta Crystallographica Section D: Biological Crystallography , vol.63 , Issue.6 , pp. 714-721
    • Huang, Y.1    Fedarovich, A.2    Tomlinson, S.3    Davies, C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.